Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

被引：0
|
作者：
Hua, Y. [1 ]
Xu, W. [1 ]
Shi, H. [1 ]
Zheng, X. [1 ]
Li, X. [1 ]
机构：
[1] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
基金：
北京市自然科学基金;
关键词：
NSCLC; MET; savolitinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12D.07
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [21] Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer
    Cao, Wa
    Li, Ai-Wu
    Ren, Sheng-Xiang
    Chen, Xiao-Xia
    Li, Wei
    Gao, Guang-Hui
    He, Ya-Yi
    Zhou, Cai-Cun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) : 6799 - 6804
  • [22] Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer
    Metzenmacher, Martin
    Christoph, Daniel C.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1254 - E1256
  • [23] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [24] First-Line Systemic Therapy for Non-Small Cell Lung Cancer
    Heist, Rebecca S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 59 - +
  • [25] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [26] Non-small cell Lung Cancer Personalization of First-Line Therapy
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [27] Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer
    Miao, Kang
    Zhang, Xiaotong
    Wang, Hanping
    Si, Xiaoyan
    Zhang, Li
    THORACIC CANCER, 2023, 14 (13) : 1162 - 1170
  • [28] Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)
    Mielgo Rubio, X.
    Gomez Rueda, A.
    Antonanzas, M.
    Falagan, S.
    Nunez, J. A.
    Pena, A. M. Sanchez
    Gomez-Barreda, I.
    Martinez Moreno, E.
    Cerezo Gonzalez, S.
    Cabezon Gutierrez, L.
    Sanchez Torres, J. M.
    Jimenez Munarriz, B. E.
    Cervera, R.
    Pangua Mendez, C.
    Calles Blanco, A.
    Lopez Martin, A.
    Lopez Castro, R.
    Sotelo Lezama, M. J.
    Perez Fernandez, E.
    Cruz, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)
    Camidge, D. Ross
    Ou, Sai-Hong Ignatius
    Shapiro, Geoffrey
    Otterson, Gregory Alan
    Villaruz, Liza Cosca
    Villalona-Calero, Miguel Angel
    Iafrate, A. John
    Varella-Garcia, Marileila
    Dacic, Sanja
    Cardarella, Stephanie
    Zhao, Weiqiang
    Tye, Lesley
    Stephenson, Patricia
    Wilner, Keith D.
    James, Leonard Philip
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Efficacy and tolerability of a weekly schedule of docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Binder, D.
    Hackenthal, M.
    Graseck, L.
    Schweisfurth, H.
    Schaeper, C.
    Kruell, M.
    Temmesfeld-Wollbrueck, B.
    Suttorp, N.
    Beinert, T.
    Hellriegel, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345